Orphan Nuclear Receptor TR3/Nur77 is a Specific Therapeutic Target for Hepatic Cancers

Yingling Zeng1, Xiaoqiang Ye2, Degui Liao3, Shizhang Huang3, Huinan Mao1, Dezhenzh Zhao1,2 and Huiyan Zeng1,2,*

Abstract

Objective: Although great success has been achieved in cancer treatment, current cancer therapies, including anti-tumorigenesis and anti-angiogenesis, still face the problems of insufficient efficacy, resistance and intrinsic refractoriness, in addition to their toxic side effects. There is a demand to identify additional targets that can be blocked to turn off the downstream effects of most, if not all, pathways. Our previous studies suggest that orphan nuclear receptor TR3 (human) / Nur77 (mouse) is such a target. However, the correlation of TR3 expression and clinical tumor progression has not been studied.

Methods: The expression of TR3 was analysed in human primary hepatic cancer specimens from patients that have complete medical records with Immunohistochemical staining. The statistical analysis was used to assess the significance of TR3 expression in tumor tissues, paratumor tissues and normal tissues, and to investigate the correlation of TR3 expression and clinicopathologic characteristics.

Results: TR3 is highly expressed in human hepatic cancer tissues, but not in normal liver tissues. The positive expression yields of TR3 are 67.67% (14/21), 19.05% (4/21) and 0% (0/10) in cancer tissues, para cancer tissues, and normal liver tissue, respectively, which are statistic significant ($\chi^2$=9.722, p<0.005). The levels of TR3 expression in human hepatic cancer tissues correlates well with tumors that are at low/middle degree of tumor differentiation and have portal vein thrombosis, metastasis and recurrence, but not with age, gender, tumor number and Alpha-fetal protein (AFP) volume.

Conclusion: The results indicate that TR3 is a specific therapeutic target for hepatic cancers.

Keywords
TR3; Nur77; Tumor; Hepatic cancer; Expression; Progression; Clinical; Correlation; Metastasis; Therapeutic target


Introduction

We were the first to identify that TR3/Nur77, a member of nuclear receptor IV subfamily of transcription factors [1], is a critical mediator of angiogenesis [2-4]. TR3/Nur77 is highly and transiently up-regulated by angiogenic factors vascular endothelial growth factor-A (VEGF-A), histamine and serotonin, but not by basic fibroblast growth factor (bFGF), placental growth factor (PLGF) and platelet-derived growth factor (PDGF) in cultured endothelial cells (EC) and during angiogenesis in vivo [2-4]. Endothelial cell proliferation, migration and tube formation induced by VEGF-A, histamine and serotonin in vitro, tumor growth, angiogenesis and micro vessel permeability induced by VEGF-A, histamine or serotonin, are inhibited by TR3 antisense DNA or shRNA in vitro and in Nur77 knockout mice, respectively [2-4]. Overexpression of TR3/Nur77 is sufficient to induce endothelial cell proliferation, migration and tube formation in vitro, angiogenesis, microvessel permeability and normal skin wound healing in our transgenic mice, in which, Nur77 full-length cDNA is inducibly and specifically expressed in mouse endothelium (EC-Nur77-S transgenic mice), respectively [2-4]. However, both the Nur77 null mice and EC-Nur77-S transgenic mice are healthy [5,6]. Therefore, TR3/Nur77 is an excellent target for pro-angiogenesis and anti-angiogenesis therapies.

It was also reported that TR3/Nur77 plays important roles in carcinogenesis, apoptosis [5], brown fat thermogenesis [7,8] inflammation, metabolism diseases, stress and addiction [9-12]. However, the clinical correlation of TR3 expression in human cancers is understudied. Hepatocellular carcinoma (HCC) that accounts for 80% of all liver cancers worldwide [13] is the sixth most common neoplasm and the third most frequent cause of cancer death [14]. In the clinic, most HCC are diagnosed in advanced stage without effective treatment [13]. Here, we examined the expression of TR3 in human hepatic cancer tissues and analysed its clinical correlation.

Material and Methods

Patient material and tissue

The paraffin-embedded postoperative tissues specimens classified by pathological analysis were obtained from the archives.
of Department of Pathology, the Second Affiliated Hospital of Guangzhou Medical University, P. R. China, between January 2010 to December 2013. Twenty-one human primary liver cancer specimens from patients that have complete medical records were retrieved. Approval of the current project was obtained from the local ethics committee.

The main characteristics of 21 patients were summarized in Table 1. Ages of all patients in this study are between 32 and 70 years (median, 58 years), with 13 cases of males and 8 cases of females. There are 8 cases and 13 cases with the tumor diameter less/equal or greater than 5 cm, respectively. Histological analysis indicated that 13 cases and 8 cases belong to low/middle and highly differentiated tumors, respectively. Among the 21 patients, 14 and 13 patients complicated with portal vein thrombosis and tumor metastasis, respectively.

Compliance with ethical standards

The research involved human samples. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University.

Tissue processing and Immunohistochemical staining

All tissues were fixed with 10% formalin, embedded with paraffin. Immunohistochemical staining on 4 µm sections was performed with an antibody against TR3/Nur77 (Univ-bio, Shanghai, CHINA), using immunological staining reagents following the protocol provided by the manufacture (Univ-bio, Shanghai, CHINA). PBS buffer was used as negative control.

Data analysis

Stained sections were analyzed by two independent pathologists. At least 10 fields with 400x amplification from each stained section were randomly chosen to be photographed with Olympus BX41 microscope (Olympus Scientific Solutions Americas Inc. Waltham, MA). Brown staining is referred as positive. Using half-quantitative measurement, the staining intensity was recorded as two levels, 1 as no staining and 2 as positive staining. The positive percentage of cancer cells was counted as 3 levels, level 1 as ≤ 25%, level 2 as 26%−75% and level 3 as ≥76%. The final score for each specimen was the multiplication of these two scores. They were referred to as high and ≥ 3 low and with <3, final score respectively. We found that the positive expression yields of TR3 are 67.67% (14/21), 19.05% (4/21) and 0% (0/10) in cancer tissues, paracancer tissues, and normal liver tissue, respectively, which are statistic significant (χ2=17.07, p<0.005). The expression of TR3 is significantly higher in cancer tissues than in paracancer tissues (χ2=9.722, p<0.005) and in normal tissues (p<0.0005) (Figure 1).

Correlation of TR3 expression and clinicopathologic characteristics

The positive expression rate of TR3 is (a) 10/15 (66.7%) cases and 4/6 (66.67%) cases for age ≥ 60 and <60, respectively; and (b) 9/13 (69.23%) cases and 5/8 (62.5%) cases for males and females, respectively (Table 1). There is no significant difference of TR3 positive expression in terms of age and sex (p>0.5). Some, but not significant, difference of TR3 expression was found in 4/9 (44.44%) cases and 10/12 (83.33%) cases for tumors with a diameter ≤ 5 cm and >5 cm, respectively (Table 1, 0.05 < *p<0.5). Expression of TR3 is significantly higher in tumors with low/middle degree of differentiation, 11/13 (84.61%) cases, than in tumors with high degree of differentiation, 3/8 (37.5%) cases. Tumors with portal vein thrombosis showed significantly higher levels of TR3 expression, 12/14 (85.71%) cases, than tumors without portal vein thrombosis, 2/7 (28.57%) cases. TR3 is expressed in 11/13 (84.61%) cases tumors with metastasis, which is significantly greater than those tumors without metastasis.

<table>
<thead>
<tr>
<th>Variables</th>
<th>No. of patients</th>
<th>Positive expression rate</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 60</td>
<td>15</td>
<td>10 (66.67%)</td>
<td>0.866</td>
</tr>
<tr>
<td>&lt; 60</td>
<td>6</td>
<td>4 (66.67%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>13</td>
<td>9 (69.23%)</td>
<td>0.557</td>
</tr>
<tr>
<td>Female</td>
<td>8</td>
<td>5 (62.5%)</td>
<td></td>
</tr>
<tr>
<td>Tumor diameter (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 5</td>
<td>9</td>
<td>4 (44.44%)</td>
<td>0.080</td>
</tr>
<tr>
<td>&gt; 5</td>
<td>12</td>
<td>10 (83.33%)</td>
<td></td>
</tr>
<tr>
<td>Degree of tumor differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low and middle</td>
<td>13</td>
<td>11 (84.61%)</td>
<td>0.040</td>
</tr>
<tr>
<td>High</td>
<td>8</td>
<td>3 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>Portal vein thrombosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With</td>
<td>14</td>
<td>12 (85.71%)</td>
<td>0.017</td>
</tr>
<tr>
<td>Without</td>
<td>7</td>
<td>2 (28.57%)</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13</td>
<td>11 (84.62%)</td>
<td>0.040</td>
</tr>
<tr>
<td>No</td>
<td>8</td>
<td>3 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>11</td>
<td>10 (90.91%)</td>
<td>0.020</td>
</tr>
<tr>
<td>No</td>
<td>10</td>
<td>4 (40%)</td>
<td></td>
</tr>
<tr>
<td>Tumor number</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>14</td>
<td>10 (71.43%)</td>
<td>0.428</td>
</tr>
<tr>
<td>Multiple</td>
<td>7</td>
<td>4 (57.14%)</td>
<td></td>
</tr>
<tr>
<td>AFP volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 400 g/L</td>
<td>12</td>
<td>9 (75%)</td>
<td>0.318</td>
</tr>
<tr>
<td>&lt; 400 g/L</td>
<td>9</td>
<td>5 (55.56%)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Correlation of TR3 expression and clinicopathologic characteristics.
metastasis, 3/8 (37.5%) cases. TR3 expression was found significantly higher in tumors with recurrence, 10/11 (90.91%) cases, than in tumors without recurrence, 4/10 (40%) cases (Table 1, all \( p<0.05 \)). Single tumors, 10/14 (71.43%) cases, did not show any difference in TR3 expression from multiple tumors, 4/10 (40%) cases. There is no difference of TR3 expression in tumors with AFP >400 µg/L, 9/12 (75%) cases, or <400 µg/L, 5/9 (55.56%) cases (Table 1, \( p>0.5 \)). These data clearly indicate that expression of TR3 in human hepatic cancer tissues correlates very well with tumors that are at low/middle degree of tumor differentiation, have portal vein thrombosis, metastasis and recurrence, somehow with tumor diameter, but does not correlate with age, gender, tumor number and AFP volume.

Conclusions

The data presented here indicate that TR3 is highly expressed in human hepatic cancer tissues, but not in human normal liver tissues. The positive expression yield of TR3 is 67.67% and 19.05% in cancer tissues and paracancer tissues, respectively. Expression of TR3 in human hepatic cancer tissues correlates very well with tumors that are at low/middle degree of tumor differentiation and have portal vein thrombosis, metastasis and recurrence, but does not have any difference in regarding of age, gender, tumor number and Alpha-fetoprotein volume.

Angiogenesis is critical for tumor growth [15-19]. Anti-VEGF neutralizing antibodies and VEGFR kinase/multiple kinase inhibitors have been successfully developed and widely used in the clinic [20]. However, in addition to their toxic side effects [21] VEGF-targeted therapies in cancer face the problems of insufficient efficacy [22-31], resistance, and intrinsic refractoriness [29,32,33]. Current anti-angiogenesis therapies mainly focus on targeting a single molecule or a single pathway, although there are some combination therapies that target a couple or a few pathways. The map of signaling pathways resembles a spider web. Hence, targeting one or a few major pathways results in other pathways becoming dominant. It is desirable to identify additional angiogenesis targets, blocking of which will turn off the downstream effects of most, if not all, pathways. Our studies found that orphan nuclear receptor TR3 / Nur77 is a master transcription factor that is down-stream of almost, if not all, signaling pathways, including VEGF-A, histamine and serotonin that control the various transcription profiles in pathological angiogenesis [2-4]. Microvessel permeability induced by VEGF-A, histamine or serotonin, and tumor growth are almost completely inhibited in Nur77 knockout mice [2-4]. However, Nur77 null mice are viable, fertile, develop an apparently normal adult vasculature [5], and have no defects in normal skin wound healing [34], suggesting that TR3 is required for pathological angiogenesis, but is not essential for developmental and physiological angiogenesis. The data that TR3 is not expressed in human normal liver tissues, but highly induced in human hepatic cancer tissues, are consistent with previous report that Nur77-/- mice 1) are viable and fertile, can develop an apparently normal adult blood vessels whereas tumor growth is inhibited in Nur77-/- mice. These finding strongly support our hypothesis that TR3 is required for pathological angiogenesis.

TR3/Nur77 is induced by epidermal growth factor (EGF) and by serum in cancer cells, and knockdown of TR3/Nur77 inhibits the proliferation of tumor cells [34]. TR3/Nur77 plays important roles in cancer cell biology [9-12]. Our results that TR3 is expressed in both endothelial cells and tumor cells correlate very well with the function
of TR3 in tumor cells. Targeting TR3 will inhibit not only tumor angiogenesis, but also tumorigenesis induced by EGF and other serum factors.

Other problems that VEGF-targeted therapy faces are resistance and intrinsic refractoriness that may be regulated by three mechanisms, 1) other angiogenic factors, such as hepatocyte growth factor (HGF) and fibroblast growth factor (FGF), regulate angiogenesis [35]; 2) tumor metastasis is increased [36]; 3) tumors increase resistance to anti-VEGF/VEGFR therapy [37]. The results obtained from current studies indicate that expression of TR3 is significantly increased in tumor tissues with metastasis and recurrence.

It was reported that TR3/Nur77 mediates VEGF-A-induced thrombomodulin expression to protect mice from arterial thrombus formation [38]. However, we found that TR3 expression is significantly increased in tumor tissues with portal vein thrombosis. The function of TR3 in mouse hepatic tumor model with or without thrombosis needs to be further studied.

In summary, we found that expression of TR3 correlates very well with the stages of hepatic cancers. To our knowledge, this is the first report about the clinical correlation of TR3 expression and human cancers. The results strongly support our previous hypothesis that TR3 is an excellent specific target for human cancers.

Consent to Publish

Informed consent was obtained from all individual participants included in the study.

Authors' Contributions

YZ and HZ have the overall responsibility to the manuscript. They contributed to design all experiments, analyze and interpret data, write and approve the final version of manuscript. DL acquired all data. SH performed analysis and interpretation of data. HM took part in analysis of Data. DZ took part in analysis and interpretation of data, and final approval of the version to be published.

Acknowledgement

This work was supported by National Institutes of Health [grant numbers RO1CA133235, R03 CA194795 and R03CA191463 to HZ] and by Guangdong Science and Technology Department [grant numbers 2012B031800491 to YZ].

References


Author Affiliations

1Departments of Preventative Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China
2Departments of Infectious Diseases, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China
3Departments of Pathology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China
4Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
5Divisions of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
6Department of Medicine, Hematology and Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA

Submit your next manuscript and get advantages of SciTechnol submissions

- 80 Journals
- 21 Day rapid review process
- 3000 Editorial team
- 5 Million readers
- More than 5000 Quality and quick review processing through Editorial Manager System

Submit your next manuscript at www.scitechnol.com/submission